Abbott Laboratories, the U.S. healthcare giant, announced plans to spin off its nutrition business into a standalone public company by the end of 2027. The company also trimmed its 2026 sales growth forecast to about 6%, a move that drew more investor attention than its latest quarterly results.
Why the split?
Abbott said the separation will allow each business to focus on its own strengths. The remaining Abbott will concentrate on medical devices, diagnostics, and established medicines, while the new nutrition company will operate independently. The nutrition unit has been a drag on Abbott's overall performance, hurt by the loss of a major U.S. government supply contract and by price increases that cooled demand.
Even Abbott's stronger engine, medical devices, showed a slight wobble. Sales in that division grew 6.9% to $5.83 billion, but that fell short of analysts' $5.88 billion estimate. JPMorgan, a global investment bank, pointed to softer growth in electrophysiology, a treatment area for heart rhythm issues.
Quarterly results vs. forward outlook
For the third quarter, Abbott's revenue edged above expectations at $13.01 billion, and adjusted earnings matched forecasts at $1.42 per share. But investors focused more on the softer 2026 growth view and whether the separation can improve the company's overall growth profile.
When a company lowers a growth target, the market often shifts from asking "how was the quarter?" to "how does the business look next year and beyond?" That shift is especially relevant here, as Abbott's 6% growth outlook for 2026 puts more weight on the end-2027 split.
What the spinoff could mean for investors
Spinning off nutrition could change how investors value Abbott. The nutrition business is more consumer-like and under pressure, while the remaining company would be more health-tech-heavy, a profile that typically commands different valuations. But the value "unlock" depends on the fine print. Splitting a company can create duplicated overhead, leave stranded costs behind, and raise questions about which business takes on debt and shared expenses.
That's why the initial share move can be driven less by a modest quarterly beat and more by whether Abbott can deliver a clean, credible path to two businesses with clearer economics. Investors will also be watching whether medical devices growth can hold up, especially in areas like electrophysiology.
For everyday investors, the key takeaway is that corporate breakups are not automatic wins. They can unlock value if each business becomes more focused and efficient, but they can also create new costs and complexities. Abbott's ability to execute the split smoothly will be a major factor in whether the move pays off.
Broader context
Abbott's move comes amid a broader trend of large healthcare companies reshaping their portfolios. Some are spinning off slower-growing units to sharpen focus on higher-growth areas, while others are making acquisitions to bolster their pipelines. The success of such moves often depends on market conditions and management execution.
Investors will likely watch for more details on the spinoff structure, including how debt and costs will be allocated, and whether the nutrition business can stabilize its revenue. The company's 2026 outlook will also be a key metric to track, as it reflects management's confidence in the core business.
What to watch next
Abbott's next earnings report will be scrutinized for updates on the spinoff timeline and any changes to the 2026 outlook. Investors will also look for signs that medical devices growth is stabilizing, and whether the nutrition business can recover from its recent setbacks.
For those holding Abbott shares, the spinoff could eventually result in receiving shares of the new nutrition company, but the exact terms are yet to be announced. As with any corporate action, it's wise to stay informed and consider how the change fits into your overall investment strategy.
